• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA seeks additional trial on Zalviso drug-device combo from AcelRx

March 9, 2015 By drugdelivery

FDA seeks additional trial on Zalviso drug-device combo from AcelRx

(Reuters) — AcelRx Pharmaceuticals (NSDQ:ACRX) said the FDA wants an additional study on its Zalviso drug-device combination, which the safety watchdog already rejected once last year.

The company, with no products in the market, said today it would not resubmit Zalviso’s regulatory application this quarter as it needed more clarity from the FDA.

ACRX shares fell as much as 42% today to an 11-month low of $5.07 in early morning trading.

Zalviso’s approval is now likely only by the end of next year, against the previous estimate of early 2016, Canaccord Genuity analyst John Newman said. Newman cut his price target on the stock to $6 from $8.

“We have pushed revenues [from Zalviso] out to 2017 end," Newman wrote in a note to investors.

The FDA told the company last week that the additional clinical study was needed to evaluate risks associated with the Zalviso device, specifically issues relating to inadvertent dispensing, AcelRx said.

Zalviso, using the opioid sufentanil, is delivered using the company’s flagship NanoTab technology that enables rapid absorption when placed under the tongue. AcelRx said it plans to meet with the agency to discuss the need for an additional trial, and its potential design and objectives.

The company had said it would resubmit Zalviso’s application by the end of 2014 after the regulator rejected the drug-device last July. The error rate in a recent test with 700 Zalviso systems was below the target error rate discussed with the FDA, AcelRx said last month.

AcelRx shares had fallen 19% through Friday’s close since FDA first rejected Zalviso late July.

Shares of Medicines Co. (NSDQ:MDCO), which is developing a similar pain drug called Ionsys, fell as much as 9.9% in early trading.

Filed Under: Drug-Device Combinations Tagged With: AcelRx

IN CASE YOU MISSED IT

  • Rapid Dose closes first tranche of $5M financing
  • Senseonics stock is up as it sticks by revenue guidance
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS